Skip to content

Clinical research of hypophosphatasia

Clinical research of hypophosphatasia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099011
Enrollment
Unknown
Registered
2025-03-17
Start date
2024-08-03
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypophosphatasia

Interventions

Patients with hypophosphatasia:Teriparatide 20ug, qn, subcutaneously.
normal people:None

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Establishing reference intervals for PLP and PPi in the Chinese population: Participants will include adult males and females aged 18–79 years with normal liver, kidney, and cardiopulmonary function, no history of excessive alcohol consumption or smoking in the recent period, no medication use, no history of surgery or hospitalization, and no history of obesity, diabetes, hypertension, malignancy, or familial genetic disorders. 2. HPP study cohort: (1) Patients with ALPL gene pathogenic mutations confirmed through genetic testing; (2) Voluntary participation in this study.

Exclusion criteria

Exclusion criteria: 1. Establishing reference intervals for PLP and PPi in the Chinese population: abnormal liver and kidney function, hypertension, diabetes mellitus, history of hyperlipidaemia, anaemia, history of malignant tumours, long term or recent blood donation, pregnancy or breastfeeding, long term smoking or alcoholism, and blood donation within 3 months. 2. HPP study cohort: (1) Other causes of low ALP levels, such as skeletal diseases (e.g., cranioclavicular dysplasia, osteogenesis imperfecta), non-skeletal diseases (e.g., Cushing's syndrome, Wilson's disease, hypothyroidism, multiple myeloma, zinc or magnesium deficiencies, vitamin B12 deficiencies, and pernicious anaemia, coeliac disease, malnutrition), and the use of drugs (e.g., anti-bone resorption drugs, glucocorticosteroids, corticosteroids, and other medications), and the use of drugs (e.g., anti-drugs). resorption drugs, glucocorticoids, oral contraceptives); (2) poor compliance and inability to follow up regularly; (3) unwillingness to participate in this study.

Design outcomes

Primary

MeasureTime frame
bone mineral density;alkaline phosphatase;PLP;inorganic pyrophoaphate;

Countries

China

Contacts

Public ContactChun Wang

Shanghai Sixth People's Hospital

wangchun66@sjtu.edu.cn+86 153 0169 0670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026